Fig. 3.
Tofacitinib treatment reduces serum soluble Fas ligand (sFasL) levels in MRL/lpr mice. Ten-week old mice (n=5, for each group) were either sham treated with formulation vehicle or tofacitinib for a period of 42 days. The serum sFasL levels were measured when they reached 7 months of age using a commercial ELISA kit from R&D systems (Minneapolis, MN) according to the manufacturer’s instructions